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A BST R A C T 
 
OBJECTIVE:  The objective of this selected EBM review is to determine whether or not 
the injection of botulinum toxin improves symptoms in patients with gastroparesis. 
 
STUDY DESIGN: Review of two published, double blind randomized controlled trials 
and one published, open label pilot study were used for this review, which were found on 
PubMed. 
 
OUTCOMES MEASURED: The outcome was the change in gastroparesis-associated 
symptoms, which was measured using the Gastroparesis Cardinal Scale Index (GCSI) 
and Gastroparesis Questionnaire. In the two double blind, randomized controlled trials by 
Arts et al. and Friendenberg et al., symptoms were quantified using the GCSI before and 
after the injection. Each of the 9 different gastroparesis-associated symptoms (nausea, 
regurgitation, vomiting, fullness, early satiety, postprandial fullness, loss of appetite, 
bloating and swollen abdomen) were graded from 0 (none) -5 (very severe), with higher 
scores indicating higher severity of symptoms. The total GCSI score was calculated by 
adding all individual symptoms severity scores. In the open-label pilot study conducted 
by Miller et al., the Gastroparesis Questionnaire was used to grade eight symptoms on a 
5-point scale from 0 (none) to 4 (extreme). A total symptom score was determined as the 
sum of each the eight graded symptoms, with a maximum of 32.  
 
RESULTS: In the study by Arts et al, symptoms improved significantly after the initial 
injection of saline or botulinum toxin. No additional improvement occurred after the 
second injection. In the study by Friedenberg et al, the group receiving botulinum toxin 
showed improvement in symptoms, however, it was not greater than the placebo group. 
In the study by Miller et al, symptom scores improved with botulinum toxin injection.  
 
CONCLUSION: The results of the two double blind, randomized controlled trials show 
that the injection of botulinum toxin is not superior to placebo in improving symptoms of 
gastroparesis. The results of the open-label pilot study indicate that botulinum toxin does 
improve symptoms.  
 
KEY WORDS: gastroparesis and botulinum toxin 
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INTRODUCTION 
Gastroparesis, or delayed gastric emptying, is a disorder that slows or stops the 
movement of stomach contents to the small intestine.1 Normally, muscles of the stomach 
contract to move food through the gastrointestinal tract.1 With gastroparesis, however, 
food is not propelled properly and contents do not empty correctly; food leaves the 
stomach slowly or does not move at all.1 
 This paper evaluates two double blind, randomized controlled trials, which 
compare the efficacy of the injection of botulinum toxin for improving symptoms of 
gastroparesis with placebo, and one open-label pilot study, which evaluates the ability of 
botulinum toxin to mend symptoms. The consideration of improving symptoms of 
gastroparesis is an important topic to discuss as the disorder is becoming increasingly 
common; it affects 9.6 per 100,000 men and 38 per 100,000 women and occurs in 80% of 
patients with dyspepsia.2,3  Additionally, over 40% of patients with diabetes have 
gastroparesis.4  As the disorder becomes more prevalent, the cost of medical care for 
gastroparesis increases as well. Although the cost in recent years is unknown, in 1998 the 
average cost for hospitalization due to gastroparesis was $6,972 per patient per month.5 
Furthermore, diabetic complications including gastroparesis totals $22.9 billion dollars.6 
Hospital admissions are also elevated; admissions with gastroparesis as the main 
diagnosis totaled 10,252 in 2004 and as the secondary diagnosis totaled 134,146 in 2004.6  
Most cases of gastroparesis are idiopathic and therefore the cause is unknown.1 
When the cause is able to be identified, diabetes is most common.1 Due to high levels of 
blood glucose that is often found with diabetic patients, damage can occur to the vagus 
nerve which leads to paralysis of stomach musculature.1 Other known causes include 
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sclerosis.1  
Symptoms of gastroparesis include nausea, fullness after a small amount of food, 
abdominal pain, abdominal bloating, and vomiting undigested food.1 Severity of the 
symptoms is highly significant, as it is the basis of how physicians treat the disorder.1 
Change in diet and careful nutrition is often the first attempt at managing gastroparesis.1 
Smaller meals and low-fat, non-fibrous foods are frequently suggested.1 In addition, 
medications can be used in management. Anti-emetics such as metoclopramide stimulate 
stomach muscle contraction and help decrease nausea and vomiting.1 Antibiotics in low 
doses, like erythromycin, may also improve gastric emptying.1 Possible side effects, 
however, include nausea, vomiting, and abdominal cramps.1 If symptoms remain 
uncontrolled, gastric electrical stimulation may be used. With this option, a battery-
operated device sends mild electrical pulses to stomach muscles to control nausea and 
vomiting.1 
Although the treatments listed above have been used to improve symptoms of 
gastroparesis, no cure exists. The proposed method of botulinum toxin injection has been 
used as treatment by acting as nerve-blocking agent.1 The toxin is injected into the 
pylorus, the sphincter between the stomach and duodenum. Botulinum toxin keeps the 
pylorus open for longer periods of time which allows food content to be passed more 
easily to the small intestine and as a result, can lead to improvement of symptoms.1  
Botulinum toxin is shown among the three trials to provide improvement in symptoms 
but not superior in comparison to placebo.7,8,9 
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OBJECTIVE 
The objective of this systematic review is to determine whether or not the 
injection of botulinum toxin improves symptoms in patients with gastroparesis. 
METHODS 
 The studies included in this review are one double blind, placebo controlled 
randomized controlled crossover trial, one double blind, placebo controlled randomized 
controlled trial, and one open label pilot study. The population studied was men and 
women with gastroparesis over the age of 18 years. The common intervention used 
among all studies was botulinum toxin injection. In the study conducted by Arts et al., 
100 units (4 mL) of botulinum toxin was injected.7 In the second randomized controlled 
trial, Friedenberg et al. used 200 units (5 mL) of botulinum toxin A.8 The open label pilot 
study used a range of 80-100 units of botulinum toxin.9 The comparison intervention in 
the two double blind, placebo controlled studies was equal volume saline solution.7,8 
Outcomes measured included change in gastroparesis-associated symptoms and were 
quantified using the Gastroparesis Cardinal Scale Index (GCSI) and Gastroparesis 
Questionnaire. 7,8,9 The GCSI measured nausea, regurgitation, vomiting, fullness, early 
satiety, postprandial fullness, loss of appetite, bloating and swollen abdomen and the 
Gastroparesis Questionnaire measured postprandial fullness, early satiety, bloating, 
epigastric discomfort, epigastric pain, postprandial nausea, belching after meals, and 
vomiting.7,8,9 
 ???????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????-reviewed journals, 
the American Journal of Gastroenterology and Alimentary Pharmacology and 
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Therapeutics.7,8,9 Articles were selected from PubMed and chosen based on relevance to 
my clinical question and address of patient-oriented outcomes (POEMS). Inclusion 
criteria included studies that were randomized controlled trials published after 1996 and 
subjects that were older than 18 years old with diagnosed, documented gastroparesis. 
Exclusion criteria consisted of patients under the age of 18 years old and studies specific 
to one cause of gastroparesis. Summary statistics were reported using: p-values, numbers 
needed to treat (NNT), and mean change from baseline.7,8,9 
OUTCOMES 
 The outcome measured was change in gastroparesis-associated symptoms using 
two questionnaires about these symptoms, the GCSI and Gastroparesis Questionnaire. 
Using the GCSI, each of the nine different gastroparesis-associated symptoms (nausea, 
regurgitation, vomiting, fullness, early satiety, postprandial fullness, loss of appetite, 
bloating and swollen abdomen) was graded from 0 (none) to 5 (very severe), with higher 
scores indicating higher severity of symptoms. The total GCSI score was calculated by 
adding all individual symptoms severity scores, with a maximum score of 45. 
 In the crossover study by Arts et al., each patient completed the GCSI 
questionnaire before the start of the study and one month after each injection of either 
botulinum toxin or saline.7 Improvement in symptoms was based on mean change from 
the baseline score.7 The study conducted by Friedenberg et al. also used the GCSI; a total 
score of  ?27 was considered moderate to severe symptoms. A ???-point reduction at one 
month after injection of the study drug was defined as improvement.8  
In the open-label pilot study by Miller et al., subjects were compared using before 
and after results of symptom scores based on the Gastroparesis Questionnaire, which 
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measures eight symptoms on a 5-point scale graded from 0 (none) to 4 (extreme).9 A total 
symptom score was determined as the sum of each the eight graded symptoms, with a 
maximum of 32.9 Improvement in symptoms was based on mean change from baseline 
score. 
Table 1. Demographics & Characteristics of Included Studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion  
Criteria 
W/D Intervention 
Arts 
(2007) 
 
Double 
blind RCT 
crossover 
23 >18  Symptoms 
suggestive of 
gastroparesis, 
established delayed 
gastric emptying 
for solids and 
liquids 
Presence of 
esophagitis, gastric 
atrophy or erosive 
gastroduodenal 
lesions on 
endoscopy, 
presence of lesions 
on small bowel x-
ray, 
major abdominal 
surgery, 
underlying 
psychiatric illness, 
use of NSAIDs, 
steroids, or drugs 
affecting gastric acid 
secretion 
0 Pyloric 
injection of 
100 units 
botulinum 
toxin A in 4 
mL of saline  
 
Fried-
enberg 
(2008) 
Double 
blind RCT  
32 18 to 
75  
Age 18-75, 
diagnosis of 
gastroparesis 
within 3 months of 
study, score of ?27 
on GCSI 
 
Pregnancy, unfit to 
undergo endoscopy, 
prior abdominal 
surgery, known 
allergy to the 
protein, prior use of 
botulinum toxin A, 
unable to stop 
medications known 
to exacerbate 
delayed gastric 
emptying 
2 Pyloric 
injection of 
200 units (5 
mL) of 
Botulinum 
toxin A 
 
 
Miller 
(2002) 
Open label 
pilot study 
10 19-
70  
Idiopathic 
gastroparesis  
Symptoms of 
nausea, vomiting, 
and/or early satiety, 
refractory to 
prokinetic agents 
Mechanical cause 
for delayed gastric 
emptying, diabetes 
mellitus, 
coagulopathy, 
pregnant or breast-
feeding 
0 Pyloric 
injection of 
80-100 units 
of botulinum 
toxin type A 
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RESULTS 
 
Two randomized controlled trials (Arts, Friedenberg) in this systematic review 
compared reported symptoms after injection botulinum toxin to placebo, while the open-
label plot study trial (Miller) compared symptoms before and after injection of botulinum 
toxin.7,8,9  The study conducted by Arts et al. was a randomized controlled, double-blind 
crossover study.7 All patients were randomized to receive botulinum toxin or saline first 
and were analyzed in those groups.7 Twelve patients received 100 units of botulinum 
toxin in 4 mL of saline and 11 patients received equal volume saline as the first 
injection.7 Prior to the start of the study and four weeks after each treatment, subjects 
completed the GCSI.7  In the group receiving botulinum toxin injections initially, the 
GCSI decreased significantly and had a mean change from baseline of -5.6 (21.3 to 
15.7).7 Four weeks later, after saline injection, no additional improvement occurred 
(13.4).7 Subjects receiving initial saline injections showed significant improvement and 
had a mean change from baseline of -5.8 (32.1 to 26.3).7 Further improvement followed 
with botulinum toxin injections which had a mean change from baseline of -4.9 (26.3 to 
21.4).7 All p-values were significant and  ?????????????????????????????????????jection, the 
p-value was <0.05 and for initial saline injections followed by botulinum toxin injections, 
p=0.002.7 
Table 2. GCSI Scores Before and After Initial Saline Treatment 
Baseline 4 weeks after initial saline 
injection 
4 weeks after botulinum 
toxin injection 
32.1 26.3 21.4 
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Table 3. GCSI Scores Before and After Initial Botulinum Toxin Treatment 
Baseline 4 weeks after initial 
botulinum toxin injection 
4 weeks after saline 
injection 
21.3 15.7 13.4 
 
The study performed by Friedenberg et al. included 32 patients who were 
assigned to a randomized group to receive botulinum toxin or placebo injections.8 Sixteen 
patients received botulinum toxin injections and the remaining 16 received saline 
injections.8 The GCSI scores were calculated before injection and one month later.8 At 
the one month follow up, six of 16 (37.5%) patients randomized to botulinum toxin and 
nine of 16 (56.3%) patients randomized to placebo had improvement in symptoms.8 The 
relative risk benefit (RBI) was calculated to -33.3% and absolute benefit increase (ABI) 
was -18.75%. Number needed to treat (NNT) was -5, meaning for every five people 
treated with botulinum toxin, one person fewer will have the expected benefit. The p-
value was 0.01 in both the experimental and control group.8 Although the group receiving 
botulinum toxin showed improvement in symptoms, it was not greater than the placebo 
group.  
Table 4. Summary of Effects of Botulinum Toxin and Placebo, One Month Post-Injection 
 Botulinum Toxin P-value Placebo P-value 
Improved % * 37.5  56.3  
GCSI -6.8 + 9.2 0.01 -10.1+ 12.7 0.01 
* Improvement defined as a >9-point reduction in the score of the Gastroparesis Cardinal 
Symptom Index. 
 
Table 5. Benefit of botulinum toxin on improvement of gastroparesis symptoms  
Placebo 
control event 
rate (CER) 
Botulinum toxin 
experimental 
event rate (EER) 
RBI ABI NNT 
56.25% 37.5% -33.3% -18.75% -5 
 
 In the third and final study, by Miller et al., 10 patients received 80-100 units of 
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botulinum toxin injections.9 Subjects completed the Gastroparesis Questionnaire before 
treatment and at two- and four-week intervals post-injection.9 Overall, nine of the 10 
patients had improvement in the total symptom score.9 The total symptom score had a 
mean change from baseline of -5 and -6.3 at two and four weeks, respectively (15.3 to 
10.3 and 9.0).9  All p-values were less than 0.05., with p=0.034 at two weeks and p= 
0.006 at four weeks. As seen in Table 6, there were also significant improvements in 
specific symptoms: postprandial fullness (p = 0.009), bloating (p = 0.017), and abdominal 
discomfort (p=0.042).9 
Table 6. Change in symptoms to botulinum toxin injection 
Symptom Before 4 weeks after injection P 
Post-prandial fullness 2.8 1.6 0.009 
Post-prandial bloating 2.6 1.5 0.017 
Post-prandial abdominal 
discomfort 
2.1 1.1 0.042 
Early satiety 1.9 1.5 0.104 
Post-prandial epigastric pain 1.7 1.0 0.111 
Post-prandial nausea 2.2 1.3 0.068 
Belching after meals 1.3 0.8 0.177 
Vomiting 0.8 0.6 0.168 
Total symptom score 15.3 9.1 0.006 
 
DISCUSSION 
 This systematic review investigated two randomized controlled trials and one 
open label pilot study to determine if botulinum toxin improves symptoms in patients 
with gastroparesis. Although all of the studies demonstrated that botulinum toxin does 
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improve symptoms of gastroparesis, the study by Arts et al. and Friedenberg et al. 
showed that botulinum toxin was not superior to placebo.7,8 The open label pilot study by 
Miller et al. revealed  significant improvement in symptoms, however, there was no 
placebo group for comparison.9 In addition, only patients with idiopathic gastroparesis 
participated in the trial.9  
 As the likelihood is high that more patients will develop gastroparesis in the 
future, botulinum toxin represents a possible alternative management.8 Botulinum toxin 
cleaves SNAP-25, which blocks the exocytosis of acetylcholine in cholinergic nerve 
endings.7 As a result, botulinum toxin can inhibit an amplified barrier function at the 
pylorus and keep the pylorus open for a longer amount of time.1,7 The injection is simple 
and has local nerve-blocking effects, as opposed to prokinetic agents, the current 
mainstay of treatment, which have marginal benefit and significant toxicities.8  
 Additionally, researchers have used botulinum toxin to treat spastic disorders of 
striated and smooth muscles by local injection into the muscle.8 For example, botulinum 
toxin has been injected into the lower esophageal sphincter for treatment of achalasia.9 
Symptoms improved temporarily for approximately three months.9   
 Limitations exist among the studies presented in this review. Sample sizes were 
narrow; the largest number of subjects was 32, in the study by Friedenberg et al., and the 
smallest number was 10, in the study by Miller et al.8,9  Future studies with a greater 
population may be necessary for further evaluation. In addition, in the study by Arts et al. 
and Miller et al., patients were evaluated one month after injection; a longer follow-up 
period may be required to adequately assess improvement in symptoms.7,9 Another 
limitation was the amount of botulinum toxin injection. In all three studies, the dose 
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ranged from 80-200 units of botulinum toxin.7,8,9 Future investigations may use higher 
doses to determine efficacy. Also, the open label pilot was not a blinded study, which 
???????????????????????????????????????????????the improvement of symptoms may 
represent a placebo response. 
CONCLUSION 
 Significant improvement in symptoms of gastroparesis with botulinum toxin 
injection was demonstrated in all three studies, however, in the two double blind, 
randomized controlled trials, botulinum toxin did not have greater results compared to 
placebo.7,8,9 Therefore, botulinum toxin does improve symptoms in patients with 
gastroparesis, but the evidence does not show superiority to placebo.7,8  Future studies 
should focus on adding more participants to increase the integrity and decrease 
limitations of the study. Researchers may also investigate different amounts of botulinum 
toxin needed to improve symptoms. Designs of future studies may use numerous 
botulinum toxin injections given over several months. Improvement of symptoms can 
then be better evaluated, as botulinum toxin is only a temporary nerve blocking agent and 
several injections may be required to achieve maximal improvement in symptoms. 
Continued research on botulinum toxin injections for the improvement of gastroparesis 
symptoms is necessary to benefit patients who do not have adequate control of symptoms 
with other treatment.  
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